Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury

C. Reichetzeder, K. von Websky, O. Tsuprykov, A. Mohagheghi Samarin, LG. Falke, SE. Dwi Putra, AA. Hasan, V. Antonenko, C. Curato, J. Rippmann, T. Klein, B. Hocher,

. 2017 ; 174 (14) : 2273-2286. [pub] 20170607

Language English Country Great Britain

Document type Comparative Study, Journal Article

E-resources Online Full text

NLK Free Medical Journals from 1968 to 1 year ago
PubMed Central from 1968 to 2020
Europe PubMed Central from 1968 to 1 year ago
Medline Complete (EBSCOhost) from 2002-01-01 to 1 year ago
Wiley Free Content from 1997 to 1 year ago

BACKGROUND AND PURPOSE: Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia-reperfusion injury (IRI) are conflicting. Here we have compared structurally unrelated DPP4 inhibitors in a model of renal IRI. EXPERIMENTAL APPROACH: IRI was induced in uninephrectomized male rats by renal artery clamping for 30 min. The sham group was uninephrectomized but not subjected to IRI. DPP4 inhibitors or vehicle were given p.o. once daily on three consecutive days prior to IRI: linagliptin (1.5 mg·kg-1·day-1), vildagliptin (8 mg·kg-1·day-1) and sitagliptin (30 mg·kg-1·day-1). An additional group received sitagliptin until study end (before IRI: 30 mg·kg-1·day-1; after IRI: 15 mg·kg-1·day-1). KEY RESULTS: Plasma-active glucagon-like peptide type 1 (GLP-1) increased threefold to fourfold in all DPP4 inhibitor groups 24 h after IRI. Plasma cystatin C, a marker of GFR, peaked 48 h after IRI. Compared with the placebo group, DPP4 inhibition did not reduce increased plasma cystatin C levels. DPP4 inhibitors ameliorated histopathologically assessed tubular damage with varying degrees of drug-specific efficacies. Renal osteopontin expression was uniformly reduced by all DPP4 inhibitors. IRI-related increased renal cytokine expression was not decreased by DPP4 inhibition. Renal DPP4 activity at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Active GLP-1 plasma levels at study end were increased only in the prolonged/dose-adjusted sitagliptin treatment group. CONCLUSIONS AND IMPLICATIONS: In rats with renal IRI, DPP4 inhibition did not alter plasma cystatin C, a marker of glomerular function, but may protect against tubular damage.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010665
003      
CZ-PrNML
005      
20180418122514.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bph.13822 $2 doi
035    __
$a (PubMed)28423178
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Reichetzeder, Christoph $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany.
245    10
$a Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury / $c C. Reichetzeder, K. von Websky, O. Tsuprykov, A. Mohagheghi Samarin, LG. Falke, SE. Dwi Putra, AA. Hasan, V. Antonenko, C. Curato, J. Rippmann, T. Klein, B. Hocher,
520    9_
$a BACKGROUND AND PURPOSE: Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia-reperfusion injury (IRI) are conflicting. Here we have compared structurally unrelated DPP4 inhibitors in a model of renal IRI. EXPERIMENTAL APPROACH: IRI was induced in uninephrectomized male rats by renal artery clamping for 30 min. The sham group was uninephrectomized but not subjected to IRI. DPP4 inhibitors or vehicle were given p.o. once daily on three consecutive days prior to IRI: linagliptin (1.5 mg·kg-1·day-1), vildagliptin (8 mg·kg-1·day-1) and sitagliptin (30 mg·kg-1·day-1). An additional group received sitagliptin until study end (before IRI: 30 mg·kg-1·day-1; after IRI: 15 mg·kg-1·day-1). KEY RESULTS: Plasma-active glucagon-like peptide type 1 (GLP-1) increased threefold to fourfold in all DPP4 inhibitor groups 24 h after IRI. Plasma cystatin C, a marker of GFR, peaked 48 h after IRI. Compared with the placebo group, DPP4 inhibition did not reduce increased plasma cystatin C levels. DPP4 inhibitors ameliorated histopathologically assessed tubular damage with varying degrees of drug-specific efficacies. Renal osteopontin expression was uniformly reduced by all DPP4 inhibitors. IRI-related increased renal cytokine expression was not decreased by DPP4 inhibition. Renal DPP4 activity at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Active GLP-1 plasma levels at study end were increased only in the prolonged/dose-adjusted sitagliptin treatment group. CONCLUSIONS AND IMPLICATIONS: In rats with renal IRI, DPP4 inhibition did not alter plasma cystatin C, a marker of glomerular function, but may protect against tubular damage.
650    _2
$a adamantan $x aplikace a dávkování $x analogy a deriváty $x chemie $x farmakologie $7 D000218
650    _2
$a zvířata $7 D000818
650    _2
$a dipeptidylpeptidasa 4 $x metabolismus $7 D018819
650    _2
$a inhibitory dipeptidylpeptidasy 4 $x aplikace a dávkování $x chemie $x farmakologie $7 D054873
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ledviny $x účinky léků $x metabolismus $x patologie $7 D007668
650    _2
$a linagliptin $x aplikace a dávkování $x chemie $x farmakologie $7 D000069476
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a molekulární struktura $7 D015394
650    _2
$a nitrily $x aplikace a dávkování $x chemie $x farmakologie $7 D009570
650    _2
$a pyrrolidiny $x aplikace a dávkování $x chemie $x farmakologie $7 D011759
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a reperfuzní poškození $x farmakoterapie $x metabolismus $x patologie $7 D015427
650    _2
$a sitagliptin fosfát $x aplikace a dávkování $x chemie $x farmakologie $7 D000068900
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a von Websky, Karoline $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Tsuprykov, Oleg $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany. Institut für Laboratoriumsmedizin, Berlin, Germany.
700    1_
$a Mohagheghi Samarin, Azadeh $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Institute of Aquaculture, University of South Bohemia, České Budějovice, Czech Republic.
700    1_
$a Falke, Luise Gabriele $u Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Dwi Putra, Sulistyo Emantoko $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Faculty of Biotechnology, University of Surabaya, Surabaya, Indonesia.
700    1_
$a Hasan, Ahmed Abdallah $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
700    1_
$a Antonenko, Viktoriia $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Curato, Caterina $u German Rheumatism Research Center (DRFZ), Berlin, Germany. Cluster of Excellence NeuroCure, Charité - Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Rippmann, Jörg $u Cardio Metabolic Diseases, Boehringer-Ingelheim Pharma GmbH&Co KG, Biberach, Germany.
700    1_
$a Klein, Thomas $u Cardio Metabolic Diseases, Boehringer-Ingelheim Pharma GmbH&Co KG, Biberach, Germany.
700    1_
$a Hocher, Berthold $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Institut für Laboratoriumsmedizin, Berlin, Germany. Department of Basic Medicine, Medical College of Hunan Normal University, Changsha, China.
773    0_
$w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 174, č. 14 (2017), s. 2273-2286
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28423178 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180418122614 $b ABA008
999    __
$a ok $b bmc $g 1288150 $s 1007477
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 174 $c 14 $d 2273-2286 $e 20170607 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...